Linked Life Data

12476271

Source:http://linkedlifedata.com/resource/pubmed/id/12476271

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2002-12-11
pubmed:abstractText
The anti-CD52 (Campath-1) monoclonal antibodies (Mabs) have a substantial history of use for controlling graft-versus-host disease in allogeneic bone marrow transplantation. Now, with the availability of a humanised form, alemtuzumab (Campath-1H), and the demonstration that this agent can reduce the tumour burden in B-CLL, a new niche may be found - as a potentially curative agent in which its tumour purging ability in vivo combines with its role as a conditioning agent in nonmyeloablative transplantation. Review of the literature shows that alemtuzumab has unique advantages as a method of depleting malignant lymphocytes, including those in patients resistant to conventional chemotherapy. Alemtuzumab can also be used in BMT for depletion of normal T and B lymphocytes of both the recipient and donor for prevention of graft rejection and GVHD. It allows good stem cell recovery with resultant rapid engraftment, has a low risk of EBV-triggered secondary malignancy and does not interfere with blood stem cell mobilisation. As a method of eliminating the malignant clone in B-CLL, alemtuzumab has shown remarkable efficacy in heavily pre-treated patients, a number of whom have progressed to autologous or allogeneic transplantation. Efficacy data are shown within the context of other transplantation data for B-CLL. These results indicate that the combination of tumour-depleting and immunosuppressive properties of alemtuzumab should be explored, with the hope of providing improved treatment options for elderly patients with advanced B-CLL or indolent lymphoma whose prognosis is too poor currently to allow treatment with traditional regimens of high-dose myeloablative chemotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0268-3369
pubmed:author
pubmed:issnType
Print
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
797-804
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:12476271-Adult, pubmed-meshheading:12476271-Aged, pubmed-meshheading:12476271-Antibodies, Monoclonal, pubmed-meshheading:12476271-Antibodies, Monoclonal, Humanized, pubmed-meshheading:12476271-Antibodies, Neoplasm, pubmed-meshheading:12476271-Antineoplastic Agents, pubmed-meshheading:12476271-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12476271-Bone Marrow Purging, pubmed-meshheading:12476271-Bone Marrow Transplantation, pubmed-meshheading:12476271-Cyclophosphamide, pubmed-meshheading:12476271-Female, pubmed-meshheading:12476271-Graft Survival, pubmed-meshheading:12476271-Graft vs Host Disease, pubmed-meshheading:12476271-Humans, pubmed-meshheading:12476271-Leukemia, Lymphocytic, Chronic, B-Cell, pubmed-meshheading:12476271-Lymphocyte Depletion, pubmed-meshheading:12476271-Lymphoma, pubmed-meshheading:12476271-Male, pubmed-meshheading:12476271-Middle Aged, pubmed-meshheading:12476271-Survival Analysis, pubmed-meshheading:12476271-Transplantation Conditioning, pubmed-meshheading:12476271-Treatment Outcome, pubmed-meshheading:12476271-Vidarabine
pubmed:year
2002
pubmed:articleTitle
Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
pubmed:affiliation
Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't